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Abstract: Most of the current knowledge on antiretroviral (ARV) drug development and 
resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the 
worldwide HIV infections. Cumulative evidence has emerged that different HIV types, 
groups and subtypes harbor distinct biological properties, including the response and 
susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are 
summarized in this review. Variations in drug susceptibility, in the emergence and selection 
of specific drug resistance mutations, in viral replicative capacity and in the dynamics of 
resistance acquisition under ARV selective pressure are discussed. Clinical responses to 
ARV therapy and associated confounding factors are also analyzed in the context of 
infections by distinct HIV genetic variants. 
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1. Introduction 
 
1.1. Genesis of HIV Types and Groups  
 
The human immunodeficiency virus (HIV) has been characterized in 1983 as the causative agent of 
the acquired immunodeficiency syndrome (AIDS) [1,2], although its presence in the human population 
has been dated back to between the 1900s and early 1920s [3,4]. From 1981 to 2008, 58 million people 
were estimated to be infected with HIV, 25 million of which have died [5]. AIDS can be considered 
one of worst pandemics in history, only paralleled to the Spanish influenza pandemic, which killed  
20–40 million people [6]. 
HIV belongs to the Retroviridae family, and to the Lentivirus genus. This genus comprises both 
types of HIV (HIV-1 and HIV-2), in addition to a large number of simian immunodeficiency viruses 
(SIV) that infect naturally different non-human primate species in the African continent [7,8].   
In their natural host, SIV rarely causes the collapse of immune system, and the detailed characteristics 
of this pathogen-host relationships remain unclear. The origin of HIV in humans was traced to multiple 
zoonotic infections, likely due to contact of hunters and butchers with corporal fluids of non-human 
primates infected with SIV [9,10]. The two HIV types have distinct origins. HIV-1 strains are closer to 
SIV that naturally infect chimpanzees (SIVcpz) [11], while HIV-2 strains are related to SIV from sooty 
mangabeys (SIVsm) [12]. The precise number of times SIVs crossed the specie barrier and infected 
humans with success will never be known, since many factors can influence the success of establishing 
infection, including: (a) the efficiency of transmissibility; (b) the capacity of avoiding the 
immunologic system; (c) a successful replication in the new host and (d) a pathogenic potential to 
guarantee human to human passage. However, the emergence of new HIV types or groups through 
novel transfer events of an SIV strain to humans is an ongoing possibility. In Central Africa, a recent 
work identified SIV circulating in risk groups that frequently have contact with corpses of primates 
killed by hunting [9]. HIV types have distinct patterns of spread and progression to AIDS. HIV-2 
infection, for example, is restricted to regions of Western and Central Africa and account for few cases 
outside that continent, representing only 1.4% of the HIV isolates characterized (Table 1).  
HIV-1 is responsible for the AIDS pandemic and can be divided into four groups (M, N, O and P), 
each one derived from a distinct introduction of SIVcpz in the human population (Table 1) [11,13].  
HIV-1 group O (Outlier) is the most divergent group (Figure 1), and it has recently been suggested it 
could have originated from SIV that infected wild gorillas (SIVgor) [13]. SIVgor is related to SIVcpz 
and thus it is possible that gorillas are an intermediate reservoir of HIV-1 group O [14]. The HIV-1O 
epidemic pattern is restricted to the West and Central Africa, and around 15,000 people are estimated 
to be infected with this variant in Cameroon [15,16]. Group N (New) was only identified in 1998 [17], 
and its origin was traced to a recombination event between the ancestor of group M and SIVcpz [18]. 
HIV-1N is very rare epidemiologically and less than 50 cases have been identified to date, all in 
Cameroon [19,20]. Recently, a new HIV-1 group (P) was described in a Cameroonian woman [21]. 
The origin of this group was correlated with SIVgor, without evidence of recombination with other 
HIV-1 groups. Currently, this is the only identified case of this variant, but other cases are expected to 
be occult in Cameroon. HIV-1 group M (Major) alone is responsible by more than 95% of the AIDS 
pandemic and virtually all studies in HIV research have been conducted with representatives of this group. Viruses 2010, 2                                       
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Table 1. Summary of HIV types and groups. 
Type  Group  Origin  Isolates (%)
1  Epidemiology  Comments 
HIV-1 M  SIVcpz 
259,678 
(98.2%) 
All continents with 
exception of Antarctica 
Major group responsible for the 
AIDS pandemic; more fit than 
HIV-1 group O and HIV-2. 
  O 
SIVgor or 
SIVcpz 
1,095 (0.4%) 
Majorly found in Central 
and West Africa 
Naturally resistant to NNRTI; less 
fit than group HIV-1 M and  
HIV-2. 
 N 
Recombinant 
group M 
ancestor / 
SIVcpz 
22 (<0.001%)  Only found in Cameroon 
Very rare epidemically; few 
studies on drug resistance 
published. 
  P  SIVgor  Single case  Undetermined 
Described in 2009 in a 
Cameroonian woman. The actual 
number of infections is unknown. 
HIV-2 —  SIVsm  3,593  (1.4%) 
Mainly found in Western 
and Central Africa; some 
cases in Western Europe, 
India, United States, 
Brazil and Japan 
Apparently slower progression to 
AIDS; less susceptible to some 
anti-HIV-1 drugs; naturally 
resistant to NNRTI. 
1 Isolates sequenced and available at the Los Alamos HIV Sequence Database as of 18 July 2009. 
Figure 1.  pol  gene nucleotide distance within HIV groups, subtypes, sub-subtypes, 
populations and intrahost quasispecies. Estimates are presented as percentages of distances. 
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1.2. HIV-1 Group M Diversity 
 
In the early 1990s the sequencing and alignment of viral genes env and gag from different strains of 
HIV-1 allowed for first time to establish the presence of well-defined HIV-1M genetic clades. Based 
on this information, subtypes A, B, C, D, E and F were recognized in 1993 [22]. In 1994, subtypes G 
and H were characterized in Central Africa, and later subtypes I (1995), J (1999) and K (2000) were 
described [23–26]. In the pol gene, the most conserved in retroviruses, the nucleotide divergence 
between HIV-1 subtypes is around 9–11% (Figure 1). 
With the advance and popularization of DNA sequencing techniques, new genomic regions were 
obtained and analyzed, including HIV-1 full-length genomes. All HIV strains previously classified as 
subtype E based on env gene phylogeny had divergent subtype A classification in gag and pol [22,27], 
revealing that HIV-1 can generate inter-subtype recombinant strains. Indeed, a “pure” subtype E has 
not been found to date. Other cases involving recombination were described for subtype G, in which 
some mosaic strains were classified as env A/gag G primarily in Central Africa [22,28,29]. The “pure” 
subtype I was evidenced as being a complex recombinant involving subtypes A, G and I [30,31]. 
According to the current classification, HIV-1 group M is divided into nine different “pure” 
subtypes or non-recombinant forms (A-D, F-H, J and K) [32]. Intersubtypic mosaic isolates are 
divided into two distinct categories: when it is found in a population (in at least three people with no 
epidemiologic link and with the same intersubtypic breakpoints), this form is classified as a circulating 
recombinant form (CRF); conversely, when it is found only in a single patient, it is classified as a 
unique recombinant form (URF). Currently, over 40 CRFs have been characterized. “Pure” subtypes E 
and I have been reclassified to CRF01_AE and CRF06_cpx, respectively. Some subtypes are further 
divided into sub-clusters denominated sub-subtypes. Genetic differences between sub-subtypes are 
around 7% in pol (Figure 1), and to date only two subtypes are divided in sub-subtypes, subtype A (A1 
through A5) and F (F1 and F2) [33–35]. 
The worldwide distribution of HIV-1 subtypes is very heterogeneous, with regional prevalence of 
specific variants (Figure 2). The most prevalent HIV-1 form is subtype C, which in 2004 was 
responsible for about 50% of the global infections [36]. It prevails in sub-Saharan countries (where 
two-thirds of all infected people are located), in Eastern African countries, in the highly populated 
India and neighbor countries and in the southern region of Brazil. Subtype A is prevalent in Central 
Africa, Iran and Eastern Europe, and in Central Asia. In all these cases, sub-subtype A1 is more 
prevalent, whereas sub-subtypes A2 and A3 are primarily found in Africa and rarely in Europe. 
Subtype B is the most disseminated variant. It predominates in developed countries, such as the United 
States, countries of Western Europe, Japan and Australia. The remaining six HIV-1 subtypes (D, F, G, 
H, J and K) represented together only 10% of new infections in 2004 [36]. Some CRFs have great 
impact in local AIDS epidemics, such as CRF01_AE in Southeast Asia and CRF02_AG in Western 
Africa. CRF06_cpx is the second most prevalent recombinant form in West Africa, while others have 
negligible epidemic relevance. 
HIV-1 molecular epidemiology is dynamic over time. For example, subtype C was dated to have 
entered Brazil in early 1980s [37–39], and recently this subtype was shown to represent 50% of new 
infections in the Brazilian southern region and 5%–30% in neighboring states [37,40–43]. While this Viruses 2010, 2                                       
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subtype is spreading in Brazil, it overgrew other subtypes in Sub-Saharan Africa practically to 
extinction, such as subtype B and D, which were common in that region in the early 1980s [44,45].  
Figure 2. Worldwide prevalence of HIV-1 group M subtypes and CRF. 
 
 
1.3. Antiretroviral Treatment Against HIV and Drug Resistance 
 
In March of 1987, AZT (zidovudine) was the first HIV-1 drug approved by the U.S. Food and Drug 
Administration (FDA) for AIDS treatment. Between 1991 and 2007, 24 additional drugs were approved, 
divided into five classes, according to the viral protein target (Table 2). Currently, the treatment 
indicated is a combination of drugs, named highly active antiretroviral therapy (HAART), which 
consists of at least three different drugs, two nucleoside reverse transcriptase inhibitors (NRTI) and a 
third, non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). Due to high 
costs, more recent antiretroviral drug classes, such as entry inhibitors (EI) and integrase inhibitors (II), 
are primarily used for salvage therapy in cases of multiple resistances to the previous classes [46]. 
HIV eradication from infected subjects is still a distant scenario, but the currently available 
treatment provides better quality of life to HIV/AIDS patients, minimizing viral replication, promoting 
partial recovery of the immune system and, thus, delaying or halting disease progression [46]. On the 
other hand, there are many obstacles to therapeutic efficacy in patients, including several adverse 
effects, limitation of drug penetration in particular reservoirs of virus replication, individual 
pharmacokinetics, treatment adherence, co-infections with other pathogens and the emergence of drug 
resistant viral strains.  
With the advent of HAART, effective viral load suppression can be maintained for many years [47,48]. 
This is a clear advance compared to the AZT monotherapy of the early days, when many patients 
presented drug resistance within a few months of continued therapy [49,50], or to dual NRTI therapy, 
when two years of treatment resulted in viral load rebound [51]. A key factor for the appearance of 
viral resistant strains is the retroviral reverse transcriptase (RT). It lacks an exonuclease proofreading 
system characteristic of cellular DNA polymerases, and is therefore prone to nucleotide 
misincorporation during cDNA synthesis, which persists in the newly synthesized copy and is Viruses 2010, 2                                       
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integrated into the host genome, producing a new variant. This repair inability of HIV RT confers a 
high mutational rate to the virus (approximately 5–10 nucleotide misincorporations per genome per 
viral cycle) [52]. Another important characteristic of HIV is its large progeny, with the generation of 
around one billion new viral particles a day in an infected individual [53]. These two factors together 
promote high viral plasticity, leading to the presence of a viral quasispecies within patients, frequent 
escape from the host immune system, and the emergence of resistant strains under drug selective 
pressure [54]. 
Table 2. Summary of antiretroviral drug classes. 
 
Drug Class  Activity  Drugs 
Release 
year 
Nucleoside/Nucleotide 
Reverse Transcriptase 
Inhibitors (NRTI) 
NRTIs are mimetics of 
nucleosides/nucleotides and bind to the active 
site of the polymerase domain in the viral RT 
enzyme, inhibiting the synthesis of double-
stranded viral cDNA 
Zidovudine (AZT)  1987 
Didanosine (ddI)  1991 
Zalcitabine (ddC)  1992 
Stavudine (d4T)  1994 
Lamivudine (3TC)  1995 
Abacavir (ABC)  1998 
Tenofovir (TDF)  2001 
Emtricitabine (FTC)  2003 
Protease Inhibitors (PI) 
PIs are mimetics of viral peptides and bind to 
the active site of the protease enzyme, 
preventing viral maturation in a late step of 
virus life cycle 
Saquinavir (SQV)  1995 
Ritonavir (RTV)  1996 
Indinavir (IDV)  1996 
Nelfinavir (NFV)  1997 
Amprenavir (APV)  1999 
Lopinavir (LPV/r)  2000 
Atazanavir (ATV)  2003 
Fosamprenavir (fAPV)  2003 
Tipranavir (TPV)  2005 
Darunavir (DRV)  2006 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTI) 
NNRTIs are designed to bind to an RT 
hydrophobic pocket, modifying its structure 
allosterically and impairing the polymerase 
domain catalytic site 
Nevirapine (NVP)  1996 
Delavirdine (DLV)  1997 
Efavirenz (EFV)  1998 
Etravirine (ETR)  2008 
Entry Inhibitors (EI) 
EIs are small peptides that bind to envelope 
viral proteins (gp41 or gp120) and prevent 
the fusion between viral envelope and 
cellular membranes or virus attachment to co-
receptors in early steps of the virus life cycle 
Enfurvirtide (T-20)  2003 
Maraviroc (MVC)  2007 
Integrase Inhibitors (II) 
IIs bind to the viral integrase and prevent the 
integration of the viral double-stranded 
cDNA into the host cellular genome in the 
early steps of the virus life 
Raltegravir (RAL)  2007 
Currently, drug resistance mutations (DRM) have been described for all drugs in clinical use. In the 
polymerase domain of RT 13 positions were correlated with loss of drug susceptibility to NRTI, and Viruses 2010, 2                                       
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14 positions to NNRTI. In the protease (PR) region, 38 positions interfere with PI susceptibility. Seven 
positions in gp41 are associated with fusion inhibitor resistance and three positions in the viral 
integrase are related to II [55]. Two types of drug resistance mutations are recognized. Those 
mutations whose presence alone causes great loss of susceptibility to one or more drugs are called 
major or principal mutations. In some cases, a single mutation can lead to cross resistance to all drugs 
within a given drug class. This is the case for L100I and Y181I/C mutations in RT, which confer 
resistance to all NNRTIs, and for I84V in protease that results in loss of activity of five out of eight 
available PIs [55]. Usually, these major DRMs are located close to the active site of the target viral 
enzyme. Enzymes with major resistance mutations are less fit than their wild-type counterparts [56–60]. 
The lost replicative capacity of the mutant enzyme is partially or fully recovered by the acquisition of 
compensatory or accessory DRM [56,61–63]. It is noteworthy that the acquisition of two or more 
accessory mutations sometimes also be implicated in the loss of drug susceptibility [55]. Of note, some 
mutations considered major to one or more drugs can act as accessory DRM to others, such as L90M, 
which is considered major to NFV and SQV and compensatory to all remaining PIs, with the exception 
of DRV [55]. 
 
2. The challenge of HIV-1 non-B subtypes 
 
An important issue extensively discussed in the last years relies on the impact of ARV drugs in 
different HIV-1 subtypes. This concern is based on the fact that the great majority of the studies 
conducted on HIV drug design, acquisition of drug resistance mutations, genotyping for drug 
resistance evaluation, and the phenotypic impact of DRM on HAART have been performed primarily 
for subtype B strains. Such concern has been particularly strengthened by two reasons. The first is the 
introduction of HIV treatment in African countries, where more than two-thirds of the people with 
HIV/AIDS live and where the HIV epidemiology is largely dominated by non-B HIV-1 subtypes 
(Figure 2). The second reason is the spreading of non-B subtypes in areas formerly recognized as 
being predominated by subtype B. In some Western European countries, the proportion of HIV-1 non-
B subtypes is greatly increased. In Portugal, for example, subtype B represented 42% of new infections 
in 2003; subtype G alone was responsible for 29% and other subtypes (C and F) and recombinants 
forms (CRF02_AG and mosaics) for another 29% of new infections [64]. In the United Kingdom, 
subtype B accounted for 52% of the infections, subtype C for 21%, and subtype A for 9%, while other 
subtypes (D, F, G, H and J) and recombinant forms were responsible for 18% of new infections [65].  
Tatt et al. (2004) showed that subtype C was responsible for 35% of new infections in heterosexual 
patients in England and Wales in 2000, while subtype B represented only 25% and subtype A, 15% of 
the infections [65]. In France, 24% of new infections were attributed to non-B subtypes (especially 
CRF02_AG) in 2001–2002 [66]. In Greece, subtype A was responsible for 42% of new infections in 
2004 vs. 33% for subtype B infections [67]. 
HIV-1 non-B subtypes represent a challenge to HAART treatment as there are scarce studies in the 
literature on the efficacy of treatment in the context of infection by these subtypes. Different HIV 
groups and subtypes carry in their genomes genetic signatures and polymorphisms that could alter the 
structure of viral proteins which are targeted by drugs, thus impairing ARV drug binding and efficacy. 
HIV-2, for example, is less susceptible to some PIs, such as amprenavir, ritonavir and   Viruses 2010, 2                                       
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indinavir [68,69]. AZT also appears to be less efficient in this HIV type [68,70]. All NNRTIs are 
equally innocuous against HIV-2 [71]. The same was observed for some HIV-1 group O isolates that 
presented naturally a cysteine at RT position 181 (181C), considered a major DRM to NNRTI [54]. 
The same study also showed the secondary NNRTI DRM 98G as a natural polymorphism in group O [72]. 
Indeed, such isolates have presented a high natural resistance to this class of inhibitors. 
Various non-B HIV-1 group M subtypes present genetic signatures and polymorphisms in their 
protease which are considered as compensatory DRM in subtype B (Table 3). These differences have 
triggered discussions as to whether those non-B subtypes are naturally less susceptible to PIs, which 
could in turn compromise the use of PI-containing HAART regimens [73–77]. The acquisition of 
various compensatory DRM can lead to therapeutic failure to PIs [55] and, on their turn, non-B 
subtype infections could fail treatment faster than those with subtype B infection. It is important to 
emphasize that no major DRM is naturally found present in HIV-1 non-B subtypes, and these concepts 
apply exclusively to compensatory mutations. 
Table 3. Genetic signatures and/or polymorphisms of HIV-1 non-B subtypes associated 
with resistance to PIs. 
Drug-associated 
mutation 
Drugs 
% in 
Subtype B 
Signatures  Polymorphisms 
I13V  TPV  13%  90%–98% in subtypes A, G 
and CRF02 
4%–78% in other 
subtypes non-B 
K20I  ATV  2%  93%–98% in subtypes G and 
CRF02 
1%–3.5% in subtypes A, 
F and CRF01 
M36I ATV,  IDV, 
NFV and TPV 
13%  81%–99% in several non-B 
subtypes  
— 
H69K  TPV  2%  96%–97% in subtypes A, C 
and G, CRF01 and CRF02 
2% in subtype F 
V82I  ATV  2%  87% in subtype G  1%–6% in several non-B 
subtypes  
I93L  ATV  33%  94% in subtype C  5%–40% in several non-B 
subtypes  
 
3. Drug Susceptibility in Treatment-Naive Patients Infected with HIV-1 non-B Subtypes  
 
In recent years, a few studies have been conducted on drug susceptibility of different HIV-1 
subtypes from treatment-naïve subjects. They have shown that drugs belonging to the PI, NRTI and 
NNRTI classes are highly efficient in inhibiting HIV-1 non-B subtypes [78–84]. There was no 
evidence that the presence of signatures and polymorphisms in those subtypes cause natural resistance 
to antiretroviral drugs. However, it has been reported that different non-B subtypes, notably subtypes 
C, F, G and CRF02_AG, presented different susceptibility to specific PIs [82,83]. A study has shown 
that subtypes C and G were more susceptible to IDV than subtype B, while CRF02_AG was more 
susceptible to NFV and RTV than subtypes B, C, F and G. Polymorphisms at PR positions 19, 35, 37, 
70 and 89 were associated with drug susceptibility and different subtypes through Bayesian network 
analysis [83]. As all PI were designed for subtype B it seems paradoxical that some subtypes are more Viruses 2010, 2                                       
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susceptible than the original target. With respect to the newer PI tipranavir, subtype F appears to be 
twofold less susceptible than other subtypes [82,83], while all subtypes are highly susceptible to 
darunavir [82]. About 10% (4/42) of subtype G isolates presented a natural lack of susceptibility to at 
least one PI, in the absence of a recognized DRM [80,84]. No case of natural resistance to PI analyzing 
31 subtype C treatment-naïve isolates [80,81], as well as 16 CRF02_AG drug-naïve isolates, has been 
found [80,84]. The remaining non-B subtypes have only a few drug-naïve isolates phenotyped, and no 
robust conclusions can be drawn. Additional studies are necessary to unequivocally elucidate the issue 
of natural resistance in HIV-1 non-B subtypes and the determinants affecting drug susceptibility in  
these variants. 
 
4. Selection of Major Drug Resistance Mutations in HIV-1 Non-B Subtypes  
 
With the advent and dissemination of HAART in countries where HIV-1 non-B subtypes are 
prevalent, studies in DRM acquisition have accumulated over recent years. Viral isolates of HIV-1 
non-B subtypes from patients under therapeutic failure primarily contain the major DRMs known for 
subtype B to PR and RT inhibitors [85–90]. On the other hand, the proportion of definite DRMs can 
differ among subtypes. For example, it is common to find the major DRM D30N in subtype B PR 
under nelfinavir exposure, but this mutation is rarely found in other subtypes [81,89,91]. A recent 
work reported that subtype F1 appears to acquire a low proportion of M46I and I84V compared to 
subtype B [92]. Such reports are in agreement with results of a global collaboration in PR and RT 
genotypes [89], where some mutations were found at a low frequency in the PR of specific non-B 
subtypes: M46L (subtype C), I84V (subtypes C, F and G) and L90M (subtypes A and F). Conversely, 
V82T was more frequent in subtype G. 
With respect to NRTIs, the frequency of mutations related to resistance to thymidine analogues 
(TAM) also show differences between subtypes. There are two well known distinct resistance 
pathways to thymidine analogues: TAM-1, which includes mutations M41L, L210W and T215Y; and 
TAM-2, characterized by mutations D67N, K70R, T215F and K219Q/E [55]. In some cases, a mixture 
of these mutational pathways can be observed. In subtype B, mutations were more frequently related to 
the TAM-1 than to the TAM-2 pathway [89], although mutations correlated with both TAM pathways 
were generally more frequent in subtype B than in other HIV-1 subtypes. Conversely, a study with 
subtype C viruses in AZT/ddI-containing HAART has shown the preferential acquisition of a mixed 
TAM pathway comprising mutations D67N, K70R and T215Y [93]. A recently published study in 
Burkina Faso showed a differential proportion of DRM in subjects infected with CRF02_AG and 
CRF06_cpx, the latter being the more prevalent form in that country [94]. Interestingly, CRF06_cpx 
appeared to accumulate NRTI DRM faster than CRF02_AG. Twenty five (69%) patients with 
CRF06_cpx presented three or more TAMs, while only three (10%) patients with CRF02_AG 
presented the same TAM numbers. Both forms presented the TAM-1 as the preferential TAM pathway. 
Treatment regimens containing the NRTI 3TC, ABC, FTC, TDF and ddI can select the uncommon 
DRM K65R [55]. This mutation is more prevalent in subtype C than in subtype B, and it is more 
prevalent in both latter subtypes than in subtype A [95,96]. 
With respect to NNRTIs, a study among pregnant women using single-dose NVP for mother-to-
child transmission prophylaxis in Uganda and Malawi showed that the proportion of viral resistance to Viruses 2010, 2                                       
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that drug was higher in subtype C (69.2%) than in subtype A (19.4%) and D (36.1%) isolates [97]. The 
proportion of NVP-resistant viruses in the newborns was also higher in those infected with subtype C 
than with subtypes A and D [98]. Mutations K103N, Y181C and Y188C were more prevalent in 
subtype C than in subtypes A and D [97,99].  
Some of the results described above remain inconclusive because there was no assessment of the 
extension of treatment exposure and the specific drug regimens of the individuals analyzed. 
Differences of B and non-B subtypes in acquiring specific DRM could be due to differences in those 
parameters; for example, more prolonged exposure of patients infected with subtype B to monotherapy 
and dual therapy, mostly available in subtype B-predominating countries in the first decade of the 
HIV/AIDS pandemic. As the use of HAART is more recent in developing countries, non-B subtypes 
have been less exposed to mono- and dual therapy, and may acquire DRM at a slower pace. At the 
same time, other factors can influence such differences, such as viral fitness in the presence of DRM, 
genetic barriers, kinetics of DRM emergence, subtype-specific mutations (SSM), polymorphisms and 
differential impact conferred by the same DRM in different subtypes. Those factors will be discussed 
in further detail below. 
 
5. Drug Resistance Mutations and Fitness 
 
Although many compensatory DRM can be naturally found in treatment-naïve isolates as 
polymorphisms or genetic signatures in different HIV-1 subtypes, the sites at which major DRM occur 
are highly conserved in HIV-1 group M isolates. The acquisition of viral resistance often implies 
structural modifications within or close to the enzyme’s active site, allowing the protein to better 
discriminate its natural substrate in the restrictive environment imposed by drugs. The cost to this 
advantage is generally paid through loss of replicative capacity. The frequency of major DRM can be 
inversely correlated with its cost to viral fitness, i.e., the higher the cost, the lower the frequency. For 
example, in a Canadian study analyzing first line HAART regimens containing AZT, ddI and NVP, 
86% of the patients presented resistance to NVP, while only 5% presented resistance to ddI and 19% 
to AZT after 30–60 weeks of treatment [100]. The genotyping of those isolates revealed that the most 
frequent mutation was K103N, followed by G190A and Y181C. A study conducted by Collins et al. 
showed that K103N-containing viruses were fitter than those containing Y181C, G190A or V106A [101]. 
With respect to PR resistance, a study conducted with patients under PI-based HAART showed that 
L90M was the commonest DRM (30%), independently of the PI used and of the number of   
PI-containing regimens, followed by V82A/F/T (20%) and D30N (16%). G48V and I84V were less 
frequently seen (<5%) [102]. In this sense, Mammano et al. showed that L90M does not severely 
affect viral fitness and that V82A reduced it in about 10% compared to wild-type viruses. On the other 
hand, the presence of G48V impaired viral replication by more than 50% [103]. Another study 
corroborated the reduced replicative loss of L90M-containing viruses and showed that the presence of 
D30N clearly affected replicative capacity [104]. It is worthwhile mentioning that all those 
experiments were conducted in HIV-1 subtype B. Therefore, the possibility that the fitness cost of the 
same mutations is different in other HIV-1 subtypes cannot be ruled out. 
Evidence that different HIV-1 subtypes can present distinct resistance fitness in the presence of 
drugs was observed, for example, for NFV. According to the IAS consensus, viral isolates under NFV Viruses 2010, 2                                       
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pressure can select D30N or L90M [55]. A study by our group showed that subtype B viruses with 
D30N or L90M had only marginal loss of replicative capacity (RC), of about 10% in relation to the 
wild type virus. On the other hand, the impact was more severe in subtype C, in which the presence of 
L90M caused a loss in RC of 20%. Subtype C with D30N alone was not able to replicate in cell  
culture [105]. The high replicative cost of D30N in subtype C could be correlated to its low acquisition 
in that subtype. 
Another well documented example of how specific mutations can impact differently on virus 
replication is that caused by TAM pathways in HIV-1 subtypes B and C. Differences were described 
for the impact on fitness when a single TAM was introduced in these subtypes [106]. The presence of 
mutations D67N and K70R did not affect the fitness of subtype B, but increased the replicative 
capacity in subtype C. Similarly, the double mutant M41L/T215Y did not affect subtype C, but it 
impacted on the fitness of subtype B. When triple mutants were compared, the results were also 
distinct. In subtype B, the fitness ranking order was: WT > TAM-1 (M41L, L210W and T215Y) 
>  TAM-2 (D67N, K70R and T215F) = TAM-1/2 (D67N, K70R and T215Y). This evidence may 
correlate to the fact that TAM-1 is more frequently seen in subtype B isolates (see previous section). 
However, in subtype C, the ranking order was: TAM-1 > WT > TAM-1/2 > TAM-2. In this case, the 
explanation for the higher frequency of mixed TAM in subtype C [93] was attributed to fact of D67N 
and K70R, both TAM-2 mutations that confer higher replicative capacity to this subtype, are selected 
earlier than TAM-1 mutations. The fact that the mixed TAM is fitter than TAM-2 explains its higher 
prevalence in subtype C. 
It is conceivable that the fitness cost is a potential cause of some differences in DRM acquisition in 
distinct HIV-1 subtypes. However, studies in this theme are still scarce in the literature. Future studies 
with new infectious clones of different HIV-1 subtypes will help to elucidate this interesting subject. 
 
6. Genetic Barriers in Different HIV-1 Subtypes 
 
The genesis of drug-resistant variants is caused by random mutation events in viral genomes during 
the reverse transcription step of the virus life cycle. The change of a nucleotide at a definite codon can 
translate into amino acid changes. Therefore, the frequency of a DRM could be directly related to the 
number of modifications in the genetic code needed for the acquisition of the amino acid conferring 
resistance. HIV-1 subtypes have silent mutations in their coding sequence that could favor the 
emergence of distinct mutations in a definite subtype or group of subtypes (Table 4). In the PR region, 
the frequency of a single mutation can be explained by genetic barrier. In subtypes B, C and F, the 
resistant variant of codon position 82 is an alanine (A), while in subtype G it is a threonine (T) [89]. 
Treatment–naïve isolates of subtype G usually have an isoleucine (I) at PR position 82, while all other 
subtypes carry a valine (V). The change of 82I into the resistant form 82A needs two transitions, while 
it requires only one transition to a change into 82T. On the other hand, it is easier for other subtypes to 
change its natural form 82V to 82A (one transition) than to 82T (two transitions) [107]. In the RT 
region, other DRM have been correlated to specific subtypes and genetic barriers, such as the case of 
mutations Q151M and L210W and their low frequency in subtype F [89,107–109]. In addition, this 
was also observed for L210W in some isolates of subtype C (30%) and more frequently in subtype G 
and CRF02_AG (above 80% of the isolates) [89,107]. A yet another example is described for V106M, Viruses 2010, 2                                       
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a cross-class NNRTI resistance mutation rarely found in clinical studies in most HIV-1 subtypes, with 
the exception of subtype C [89,110–113]. In this case, subtype C needs only a transition to acquire 
V106M, while all remaining subtypes require two transitions [106,110]. 
Table 4. Drug resistance mutation and genetic barriers for HIV-1 group M subtypes 
Codon Position 
(pol genomic 
region) 
Resistance 
mutation 
Codon change  Genetic barrier in non-B subtypes 
82 (PR) 
V82A 
V82T 
GTC → GCC (1 ts) 
GTC → ACC (2 ts) 
G: 14% GTC 
Other subtypes: 87%–100% GTC 
82 (PR) 
I82A 
I82T 
ATC → GCC (2 ts) 
ATC → ACC (1 ts) 
G: 84% ATC 
Other subtypes: 0%–9% ATC 
118* (RT)  V118I 
GTT / GTC / GTA → ATT / 
ATC / ATA (1 ts) 
GTG → ATA (2 ts) 
G: 63% ATA 
Other subtypes: 0%–6% ATA 
151 (RT)  Q151M 
CAG → ATG (2 tv) 
CAA → ATG (1 ts, 2 tv) 
D: 37% CAA 
F: 83% CAA 
Other subtypes: 2%–12% CAA 
210 (RT)  L210W 
TTG → TGG (1 tv) 
TTA / CTG → TGG (1ts, 1 tv) 
CTA → TGG (2 ts, 1 tv) 
C: 30% TTA / CTG 
F: 50% TTA / CTG and 23% CTA 
G: 82% TTA / CTG 
CRF02_AG: 83% TTA / CTG 
Other subtypes: 82%–87% TTG 
106 (RT)  V106M 
GTG → ATG (1 ts) 
GTA → ATG (2 ts) 
C: 83% GTG 
Other subtypes: 0–7% GTG 
108* (RT)  V108I 
GTA → ATA (1 ts) 
GTG → ATA (2 ts) 
G: 62% GTG 
Other subtypes: 88%–100% 
Data extracted from reference [103]; * Secondary DRM; ts – transition; tv - transversion 
Yet another interesting case of genetic barrier for DRM and subtypes is the NRTI mutation K65R. 
It was shown that in HIV-1-infected cell cultures treated with TDF, that mutation was selected more 
rapidly in subtype C (12 weeks) than in subtype B (34–78 weeks) [114]. In the same experiment, 
viruses of subtypes A, G, CRF01_AE and CRF02_AG did not develop K65R during 30–33 weeks. 
The impairment caused by this mutation in the replicative capacity was similar in subtypes B and C. 
All the viral isolates tested in this study were derived from samples isolated from patients’ peripheral 
blood mononuclear cell (PBMC) co-culture, and therefore were clinically relevant. Another study by 
the same group showed faster acquisition of K65R in subtype C in cell culture with ABC (22–30 
weeks), ddI (22–30 weeks) and TDF (12 weeks), while subtype B and HIV-2 isolates did not select for 
this mutation after 22–30 weeks in the presence of these drugs [115]. The combination of two NRTIs 
in the same cell culture also resulted in K65R acquisition in subtype C isolates in 12–30 weeks, but not 
in subtype B or HIV-2 isolates. Both subtypes B and C need only a transition to acquire this mutation. 
In this case, the explanation relied on differences at polymorphic sequences at RT codons 64 and 65 in 
these subtypes. Subtype B has AGG AAA at these codons, while subtype C has AAA AAG. This 
adenine-rich run exclusively present in subtype C appears to cause a pause in RT during the (+) strand Viruses 2010, 2                                       
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DNA synthesis step, favoring nucleotide misincorporation and increasing the chance of K65R 
occurrence [116]. Clinical studies corroborated these data, showing a higher accumulation of K65R in 
subtype C [117–119]. This is the first example of the impact of silent mutations outside a resistance 
codon which are correlated with the acquisition of drug resistance in HIV. 
Genetic barrier may explain some cases of differential emergence of DRM. Nonetheless, the 
mutational cost to acquire major DRM is generally similar in the most prevalent HIV-1 subtypes and 
CRF (A-D, F, G, J, CRF01_AE and CRF02_AG). This indicates that genetic barrier is not the sole 
cause of differences in DRM acquisition observed among HIV-1 subtypes. 
 
7. Kinetics of DRM Emergence 
 
Another potential mechanism to explain distinct prevalence of DRM between subtypes is 
differential kinetics for DRM acquisition across drug exposure time. However, there are only a few 
studies on this issue to date. Such studies nevertheless showed some interesting differences. For 
example, in Brazil, it has been shown that subtype C isolates from patients under antiretroviral 
treatment accumulate lower rates of DRM to NRTIs and PIs than isolates of subtype B [120]. After 
five years under NRTI-containing HAART, 45% of subtype B isolates presented at least one major 
DRM to that class, while subtype C isolates presented only 19% in the same period. For PI, after the 
same time, 36% of the subtype B isolates had at least one major DRM vs. only 6% of subtype C 
viruses. The kinetics of DRM acquisition was similar in both subtypes for NNRTIs. Another study 
showed that isolates of sub-subtype F1 under NFV-containing regimen accumulates L90M slower than 
subtype B (5% vs. 16%, respectively) after three years of treatment [92]. However, subjects infected 
with subtypes B and G from Portugal did not present differences in the proportion of resistant strains 
after four years under a NFV-based HAART regimen [121]. In this case the lower presence of D30N 
in subtype G was compensated by higher acquisition of L90M. On the other hand, subtype G had a 
lower frequency of IDV resistance (20%) than subtype B (40%) after six years of treatment. 
The explanation behind this phenomenon remains unclear. Studies about fitness in major DRM for 
non-B subtypes are yet scarce as previously discussed. These studies show that in some cases, non-B 
subtypes had a lower frequency of DRM acquisition across treatment exposure time than subtype B, 
for which all available drugs have been designed. 
 
8. HIV Subtype-specific Mutations 
 
Another possible explanation for the differential kinetics of DRM acquisition between subtypes 
would be the emergence of subtype-specific mutations (SSM) that compensate for the lower 
proportion of recognized DRM compared to subtype B. The first SSM described was M89I/V for 
subtypes C, F and G [122]. This mutation was more frequent in patients failing PI-based HAART with 
major DRMs. However, phenotyping of isolates carrying M89I/V characterize it as a secondary DRM. 
Isolates of subtypes C, F and G with M89I/V and L90M had two-fold decreased susceptibility to NFV 
compared to that of isolates carrying L90M alone. Bayesian analysis correlated these mutations with 
A71T and T74S. Another work showed that PR clones of subtype G isolates without these latter Viruses 2010, 2                                       
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mutations reversed 89I/V to 89M [123]. More recently, we showed that M89I is essential in subtype G 
to confer high level of resistance to NFV and SQV in clinical isolates with L90M [122]. 
Other mutations have also been correlated with treatment, such as those at PR positions 6 (subtype C), 
15 (CRF02_AG), 19 (subtype F), 37 (subtype A) and 64 (subtype C and CRF01_AE), in addition to 
RT position 102 in subtype C [89]. However, their actual role in drug resistance remains unknown. 
Another recent study has associated the PR substitutions V13A (IDV, APV and LPV), D35N (NFV), 
I66F (IDV) and I82M (IDV and LPV) with PI treatment in subtype G by regression analysis [124]. 
Subtype-specific mutations require careful phenotypic characterization, since the identification of 
mutation as a major DRM will drastically change the resistance genotyping interpretation for a given 
subtype or group of subtypes. Most importantly, the correct interpretation of SSM will better guide 
treatment in countries where non-B subtypes prevail. 
 
9. Polymorphisms and Signatures in Non-B Subtypes Correlated with DRM 
 
HIV-1 subtypes have genetic signatures and amino acid polymorphisms that cause conformational 
changes at their proteins and such hindrances can facilitate or impair the acquisition of definite DRM. 
Interesting examples are mutations N88D and N88S in PR. They are both selected under NFV 
pressure. However, in clinical isolates of subtype B with at least either mutation D30N, N88any or 
L90M, or a combination of these, N88D was present in 21.2% of patients, compared to a prevalence of 
N88S in only 5.2% of patients [125]. N88D is classified as compensatory DRM and is strongly 
correlated with the D30N resistance pathway. Subtype B isolates with D30N and N88D are fourfold 
less susceptible to NFV (mean fold-change (FC) = 50) than isolates with D30N alone (mean FC = 14). 
However, the presence of N88S was negatively correlated with D30N and isolates carrying N88S 
presented a mean FC of 11, similar to D30N, defining the former as a major DRM. N88S confers 
hypersusceptibility to APV [125,126]. In other clinical studies, N88S was more frequently found in 
isolates of CRF01_AE than in subtype B [89,91]. N88S was also more frequent in subtype F than 
subtype B in Brazil [92]. Molecular dynamics simulations with PR-NFV complexes of subtypes B 
(wt), B-D30N, B-N88S, CRF01_AE (wt), CRF01_AE-D30N and CRF01_AE-N88S showed 
discordant results [127]. In subtype B, D30N reduces the energy of binding to NFV more than does 
N88S. The opposite was observed in CRF01_AE, which could explain the differential prevalence of 
those mutations in these two subtypes. Proteases of CRF01_AE used in this study carried some natural 
polymorphisms (K20R, E35D and I93L) and signatures (M36I, R41K, H69K and L89M) that interfere 
in the differential acquisition of D30N and N88S, particularly the signature M36I [128]. This study 
hypothesized that such signatures make D30N less effective against NFV in non-B subtypes. 
 
10. Differential Resistance Conferred by the Same DRM 
 
The classification of DRM into major or compensatory mutations is exclusively based on data 
generated with subtype B. For example, mutation L90M in PR of subtype B is considered major to 
NFV and SQV and compensatory to other PI [55]. Other instances include most of the major DRM in 
PR: V32I, L33F, M46I/L, I47V, I50V, V82A/F/T/S and I84V. However, it is conceivable that such 
classification might not hold true for non-B subtypes. Because of subtype-specific amino acids and Viruses 2010, 2                                       
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therefore structural backbones, the same mutation can confer different levels of susceptibility to a 
given drug. In isolates of subtype G under NFV-containing treatment the commonest pattern found 
was an association between M89I and L90M (21%), while L90M alone was seen in only 10% of 
patients [121]. Changes at PR codon 89 in subtype B isolates were not observed. L90M alone in 
isolates of subtype G conferred a mean twofold drop in susceptibility to NFV (FC = 2.1), while the 
same mutation in subtype B conferred a sevenfold decrease (FC = 7.6). However, subtype G isolates 
carrying M89I/L90M have an FC to NFV similar to that of L90M alone in subtype B. Interestingly, 
subtype G isolates with L90M alone or M89I/L90M did not show resistance to SQV, while in subtype 
B L90M alone was able to confer decreased susceptibility of about 3.5 times to that PI. Another 
mutation observed in this resistance pathway was I54V/L. Its presence with L90M doubled the FC to 
SQV, while I54V/L per se did not have any impact for that drug. 
Differential resistant phenotypes have also been observed in subtypes B and C carrying the PR 
mutation T74S. This mutation was described as compensatory, increasing the replicative capacity of PI 
multiply-resistant viruses of both subtypes [129]. Its presence also increased the susceptibility to most 
PIs in subtypes B and C. However, some phenotypic effects diverged between them. Subtype B clones 
with DRMs M46I, I54V, V82A and L90M and with T74S showed a resensitization of the virus to 
IDV, while subtype C clones with the same mutations remained resistant to that drug. T74S in multi-
resistant viruses also decreased the FC of subtype B to SQV (11.7 to 2.0), to LPV (12.8 to 2.8) and to 
RTV (240 to 7.0). However, such resensitization was less pronounced in subtype C to LPV (189 to 29) 
and to RTV (303 to 25.7).  
In the viral RT, mutation K65R conferred a more pronounced resistant phenotype to ABC, 3TC and 
ddI in CRF01_AE than in subtypes B and C [114]. A recent report also showed differences in the 
resistance levels conferred by TAMs to AZT in subtype B and CRF01_AE [130]. The TAM-1 pathway 
(M41L, L210W and T215Y) conferred a higher fold-resistance to CRF01_AE (51×) than to subtype B 
(17×) compared to their respective wild-type clones. Similar results were obtained for the TAM-2 
pathway (D67N, K70R, T215F and K219Q) in CRF01_AE (64×) and subtype B (13×). The cause of 
this difference was mapped to the change A400T in RT, a signature present in CRF01_AE. When the 
threonine was reverted to alanine in CRF01_AE RT, the resistance level was similar to that of subtype 
B. This represents the first experimental evidence that a natural signature directly influences resistance 
levels to antiretroviral drugs in different subtypes. 
Subtype-specific protein backbones, in addition to affecting fitness or facilitating DRM acquisition, 
can also confer different resistance levels to definite HIV-1 group M subtypes. Studies in this area are 
novel and can help improve current genotyping algorithms, essential to guide better salvage regimens 
in patients failing therapy. 
 
11. Impact of HIV-1 Subtype on Therapeutic and Clinical Response 
 
With the expansion of antiretroviral treatment throughout the world, HAART has been introduced 
in countries where non-B subtypes are prevalent. This scenario created an opportunity to evaluate 
patients’ response with respect to HIV viral load (VL) decrease and CD4
+ T-cell recovery in the 
context of distinct HIV-1 subtypes. A study in Europe compared treatment response of European 
patients, all infected with subtype B, with that of African immigrants, the majority of which infected Viruses 2010, 2                                       
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with subtypes A, C and D [130]. For this comparison only patients in their first-line HAART regimen 
were enrolled. The time to HIV VL undetectability (<500 RNA copies/mL) was strikingly similar for 
both groups after 12 months of therapy (>90%). The CD4
+ T-cell recovery was also similar between 
groups during the first 21 months of treatment. Another study in France with patients infected with 
subtype B (76%) and non-B (24%) in first-line regimen also failed to denote differences in HIV VL 
control and in CD4
+ T-cell recovery [132]. In this study, however, “non-B subtypes” were pooled 
together, preventing the observation of any differences between the subtypes present. Other studies in 
developed countries corroborated the lack of influence of subtype on patient’s response to HAART 
[133–135]. A study in Angola with patients in first-line triple drug combination showed that a great 
part of them was under HIV VL control (74%) after one year of treatment, irrespective of the infecting 
subtype [136]. Interestingly, a recent work in England with patients infected with subtypes A, B and C 
showed that VL suppression occurred more rapidly in subtypes A- and C- than in subtype B-infected 
subjects [137]. Moreover, the latter showed higher CD4
+ T-cell recovery rates compared to the 
remaining subtypes. 
An important confounding factor present in several of the studies that compared the effect of 
subtype on treatment outcome is the ethnicity of the subjects. Even in cases where patients were 
enrolled from a single care site, differences in cultural aspects of individuals from diverse geographic 
locales or continents may play an important role in the outcome. Adherence to treatment is a clear 
example of those aspects. Indeed, one of the studies that found a “subtype effect” on treatment 
outcome was able to associate ethnicity with virologic responses [138], therefore preventing a clear 
distinction between the ethnicity and subtype factors. 
HIV strains with higher genetic distances to HIV-1 group M seem to be more prone to failing 
clinical outcomes. A meta-analysis conducted with Belgian and Luxembourgian patients comparing 
clinical outcomes after 12 months of treatment upon HIV-1 or HIV-2 infection showed reduced 
immunologic and virologic responses in the latter group [139]. The use of PI improved the response of 
the HIV-2-infected patients as opposed to the exclusive use of RTI. This is an important drug 
combination against HIV-2, where NNRTIs are ineffective as previously discussed. 
It is apparent from the abovementioned studies that first-line HAART regimens are similarly 
efficient in suppressing HIV VL and CD4
+ T-cell recovery in patients infected with different HIV 
strains. Whether people infected with diverse subtypes have differences in clinical outcomes after 
long-term treatment remains to be elucidated. 
 
12. Conclusions 
 
As the technology for the achievement of HIV eradication and of the formulation of an effective 
sterilizing HIV vaccine are still beyond our knowledge, antiretroviral therapy is yet to be further 
disseminated in the next future, particularly in developing countries. As a consequence, the 
understanding of the impact of HIV genetic diversity on the development of drug resistance and on 
treatment outcomes is of pivotal importance. Such knowledge concerns not only to developing, but 
also to developed nations, where the proportion of new HIV infections by non-B subtypes is currently 
rising sharply. The use of antiretroviral drugs, originally developed for subtype B, is so far similarly 
promising in geographical areas where non-B subtypes circulate. However, only long-term studies Viruses 2010, 2                                       
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assessing the susceptibility to antiretroviral drug regimens in settings where non-B subtypes occur will 
be of paramount relevance to trace the role of the described polymorphisms / molecular signatures in 
the dynamics of drug resistance acquisition. Such studies should resolve and unequivocally discard 
confounding issues such as ethnicity and adherence. They should also avoid pooling non-B subtypes as 
a unique genetic entity, as they are as distinct from each other as they are from subtype B. Initiatives to 
extend ARV access in the developing world should permit additional, more structured trials to evaluate 
these issues. Most importantly, the enormous reductions seen in mortality and morbidity of HIV-
infected individuals in resource-poor settings consequent to ARV access constitutes the proof-of-
principle that HIV genetic variation should not be a reason to withhold worldwide dissemination of 
treatment. 
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